发明名称 Transdermal administration of lasofoxifene
摘要 <p>The present invention to provide methods, pharmaceutical formulations, and devices for the transdermal delivery of 5-substituted-6-cyclic-5,6,7,8,-tetrahydronaphthalene2-ol compounds ("lasofoxifene" or "CP-336,156") and pharmaceutically acceptable salts thereof. The invention also provides transdermal compositions of CP-336,156 or its salts dissolved or dispersed in a suitable carrier vehicle, optionally containing permeation enhancers and other excipients. The carrier vehicle may be a pressure sensitive adhesive, polymeric reservoir, or a fluid of controlled viscosity. The carrier vehicle may be contained in a device for purposes of holding the composition against the skin surface. Such devices may be in the form of matrix patches (drug in adhesive) or reservoir patches (drug in a liquid or polymeric reservoir with peripheral, in-line, or over-layed pressure sensitive adhesive). Further provided by this invention are methods for treating pathologies associated with the binding of lasofoxifene with the human estrogen receptor-alpha. For example, the invention formulations and devices are useful to treat or prevent bone loss, obesity, breast cancer, endometriosis, cardiovascular disease and prostatic disease.</p>
申请公布号 CZ20020488(A3) 申请公布日期 2002.06.12
申请号 CZ20020000488 申请日期 2001.05.31
申请人 WATSON PHARMACEUTICALS, INC. 发明人 FIKSTAD DAVID;QUAN DANYI
分类号 A61K9/00;A61K9/70;A61K31/40;A61K31/445;A61K31/46;A61K47/10;A61K47/14;A61P5/30;(IPC1-7):A61K9/70;A61P3/04;A61P9/00;A61P13/08;A61P35/00;A61P19/10 主分类号 A61K9/00
代理机构 代理人
主权项
地址